I find the commentary from Jon and the board fascinating re: 2591. I have been invested in the past in a number of companies that talk up a asset and fail spectacularly then the results / assays (for materials) come in. Neuren certainly does not need to pump the price to help it raise in the future. If anything, financially, the problem they will have in the next couple of years is what to do with the hoard of cash they are accumulating. So no pump for capital raise - that is clear.
Second, the study is open label (so no placebo control) and the participant numbers are not so high so statistically - this phase has limits (although across 4 diseases there are 80-100+ patients - so this makes any overall findings about 2591 more robust).
Yet they are outwardly super positive / confident. So, either the lab studies are among the very best as suggested or anecdotal feedback from those participants is so compelling they cant hide it very well.
Either way, they are not biotech rookies. They know exactly what they are saying and doing imo.
I find the commentary from Jon and the board fascinating re:...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.25 |
Change
0.430(2.17%) |
Mkt cap ! $2.585B | |||
| Open | High | Low | Value | Volume |
| $19.89 | $20.39 | $19.77 | $5.715M | 283.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 355 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.29 | 302 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.22 |
Change
0.430 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $19.86 | $20.40 | $19.77 | 85257 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| NEU (ASX) Chart |